RESHAPE LIFESCIENCES INC. ReShape Lifesciences Inc. Share Price
Equities
RSLS
US76090R2004
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.1664 USD | -0.36% |
|
-4.42% | -33.36% |
| 04-12 | North American Morning Briefing : Big Banks Kick -2- | DJ |
| 04-01 | Transcript : ReShape Lifesciences Inc., Q4 2023 Earnings Call, Apr 01, 2024 |
| Sales 2024 * | 9.99M 794M | Sales 2025 * | 11.99M 953M | Capitalization | 3.92M 311M |
|---|---|---|---|---|---|
| Net income 2024 * | -6M -477M | Net income 2025 * | -5M -397M | EV / Sales 2024 * | 0.39 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 0.33 x |
| P/E ratio 2024 * |
-0.37
x | P/E ratio 2025 * |
-0.46
x | Employees | 29 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 88.83% |
More Fundamentals
* Assessed data
More news
Latest transcript on ReShape Lifesciences Inc.
More recommendations
More press releases
| 1 day | -0.36% | ||
| 1 week | -4.42% | ||
| Current month | +0.24% | ||
| 1 month | +1.03% | ||
| 3 months | +4.98% | ||
| 6 months | -29.97% | ||
| Current year | -33.36% |
1 week
0.16
0.18
1 month
0.160.18
Current year
0.140.30
1 year
0.142.76
3 years
0.14475.00
5 years
0.14720.00
10 years
0.141 000 000.00
| Managers | Title | Age | Since |
|---|---|---|---|
Paul Hickey
CEO | Chief Executive Officer | 59 | 31/01/20 |
| Director of Finance/CFO | 63 | 14/06/21 | |
Dov Gal
CMP | Compliance Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Gary Blackford
BRD | Director/Board Member | 66 | 31/12/15 |
Dan Gladney
CHM | Chairman | 70 | 31/10/15 |
| Director/Board Member | 70 | 14/06/21 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 14/05/24 | 0.1664 | -0.36% | 195,617 |
| 13/05/24 | 0.167 | -0.60% | 153,559 |
| 10/05/24 | 0.168 | +0.18% | 82,651 |
| 09/05/24 | 0.1677 | -4.17% | 84,901 |
| 08/05/24 | 0.175 | +0.52% | 241,469 |
Delayed Quote Nasdaq, May 14, 2024 at 09:00 pm
More quotes
ReShape Lifesciences Inc. is a weight-loss and metabolic health-solutions company. The Company offers an integrated portfolio of products and services that manage and treat obesity and metabolic disease. Its Lap-Band System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures, such as gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim Neuromodulation (DBSN) system utilizes a vagus nerve block and stimulation technology platform for the treatment of type II diabetes and metabolic disorders. The Obalon balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. Its ReShape Calibration tubes are multifunctional devices compared to reusable bougies and disposable gastric tubes. Its Lap-Band 2.0, like the original Lap-Band System, is designed to provide minimally invasive long-term treatment of severe obesity.
Calendar
19/05/2024
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.167
USD
Average target price
1
USD
Spread / Average Target
+498.80%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -33.36% | 3.92M | |
| +12.06% | 225B | |
| +12.07% | 186B | |
| +13.88% | 135B | |
| +27.12% | 107B | |
| +0.91% | 63.56B | |
| +6.74% | 51.32B | |
| +13.39% | 51.04B | |
| +8.81% | 43.3B | |
| +4.14% | 36.99B |
- Stock Market
- Equities
- RSLS Stock
